The global Addison’s Disease Market is anticipated to grow at a considerable CAGR during the forecast period (2021-2027). The growth of the market is mainly attributed to the increase in the prevalence of Addison’s disease, rising R&D activities to produce new drugs for diagnosis and increasing awareness about Addison’s disease among the population across the globe. The advancement in technologies and several government initiatives also played a vital role in contributing to the growth of the market. Besides, major market players such as Pfizer Inc. GlaxoSmithKline plc, Lupin Pharmaceuticals, Inc., Novartis AG are adopting various strategies such as mergers & acquisition, new product launches, business expansion, and technology innovation to remain competitive in the market.
Browse the full report description of "Global Addison’s Disease Market Size, Share & Trends Analysis Report by Diagnosis (Laboratory Testing and Imaging Tests), By Treatment (Oral Corticosteroid and Corticosteroid Injections), By End User (Hospitals and Clinics, and Diagnostic Laboratories) Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/addison-disease-market
The approvals from the FDA for the drugs produced by major market players expected to propel the growth of the market. For instance, in September 2020, Diurnal Group plc had announced that the US Food and Drug Administration (FDA) has approved Alkindi Sprinkle (hydrocortisone granules in capsules for opening). The Alkindi Sprinkle is the replacement therapy for adrenal insufficiency (AI) in infants, children and adolescents (from birth to <18 years old). Besides, the strategic partnership among the market players is also growing which lead to the production of these medicines on a larger level. For instance, Citrine Medicine, a China-based rare disease therapeutics company had announced a partnership collaboration with Diurnal Group Plc to develop, register and commercialization Alkindi in the China market. However, the lack of awareness and inability to diagnose Addison’s disease in starting phase can be a restrain to market growth. further, the investment and initiatives by many pharmaceutical companies can offer lucrative opportunities in the market.
Market Coverage
o By Diagnosis
o By Treatment
o By End-User
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Addison’s Disease Market Report Segment
By Diagnosis
By Treatment
By End-User
Global Addison’s Disease Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/addison-disease-market